MX2007016060A - Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. - Google Patents
Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.Info
- Publication number
- MX2007016060A MX2007016060A MX2007016060A MX2007016060A MX2007016060A MX 2007016060 A MX2007016060 A MX 2007016060A MX 2007016060 A MX2007016060 A MX 2007016060A MX 2007016060 A MX2007016060 A MX 2007016060A MX 2007016060 A MX2007016060 A MX 2007016060A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- interferon
- cytokine
- family
- cardiotrophin
- Prior art date
Links
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 159
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 159
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 145
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 145
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title description 7
- 102000004889 Interleukin-6 Human genes 0.000 title description 3
- 229940100601 interleukin-6 Drugs 0.000 title description 3
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims abstract description 87
- 108010041776 cardiotrophin 1 Proteins 0.000 claims abstract description 87
- 108090000630 Oncostatin M Proteins 0.000 claims abstract description 57
- 102000004140 Oncostatin M Human genes 0.000 claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 34
- 230000003612 virological effect Effects 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims abstract description 13
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims abstract description 13
- 102000003815 Interleukin-11 Human genes 0.000 claims abstract description 13
- 108090000177 Interleukin-11 Proteins 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 108010002871 cardiotrophin-like cytokine Proteins 0.000 claims abstract description 6
- 208000032839 leukemia Diseases 0.000 claims abstract description 6
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 73
- 229920001184 polypeptide Polymers 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000014150 Interferons Human genes 0.000 claims description 22
- 108010050904 Interferons Proteins 0.000 claims description 22
- 229940079322 interferon Drugs 0.000 claims description 21
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 230000001766 physiological effect Effects 0.000 claims description 10
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 8
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 description 75
- 210000004027 cell Anatomy 0.000 description 68
- 108010078049 Interferon alpha-2 Proteins 0.000 description 58
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 39
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 37
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 37
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 31
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 31
- 230000000840 anti-viral effect Effects 0.000 description 30
- 230000004913 activation Effects 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 241000710188 Encephalomyocarditis virus Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 102100039948 Interferon alpha-5 Human genes 0.000 description 11
- 101710127457 Interferon alpha-5 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 6
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 4
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 4
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 4
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102000026633 IL6 Human genes 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 208000026375 Salivary gland disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- 238000012232 AGPC extraction Methods 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101800001169 Protein p48 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5415—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501468A ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| PCT/ES2006/000353 WO2006134195A2 (es) | 2005-06-16 | 2006-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007016060A true MX2007016060A (es) | 2008-03-10 |
Family
ID=37532659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007016060A MX2007016060A (es) | 2005-06-16 | 2006-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7829077B2 (https=) |
| EP (1) | EP1905447A4 (https=) |
| JP (1) | JP5154412B2 (https=) |
| CN (1) | CN101257918B (https=) |
| AU (1) | AU2006258966B8 (https=) |
| BR (1) | BRPI0611988A2 (https=) |
| CA (1) | CA2612282C (https=) |
| ES (1) | ES2302402B1 (https=) |
| MX (1) | MX2007016060A (https=) |
| RU (1) | RU2413529C2 (https=) |
| WO (1) | WO2006134195A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009762A1 (en) * | 2008-07-23 | 2010-01-28 | United Technologies Ut Ag | Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection |
| JP2010059081A (ja) * | 2008-09-02 | 2010-03-18 | Okayama Univ | オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用 |
| ES2342529B1 (es) * | 2008-10-07 | 2011-05-11 | Proyecto De Biomedicina Cima, S.L. | Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas. |
| US20120308517A1 (en) * | 2010-02-09 | 2012-12-06 | Digna Biotech, S.L. | Compositions for the treatment of infectious and tumoural diseases |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018178215A1 (en) | 2017-03-31 | 2018-10-04 | Accanis Biotech F&E Gmbh & Co Kg | Prevention and treatment of non-melanoma skin cancer (nmsc) |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN113197910B (zh) * | 2021-05-14 | 2022-09-23 | 苏州大学 | 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284237B1 (en) | 1986-07-08 | 2001-09-04 | Steven C. Clark | Methods of treatment using IL-6 |
| IE67035B1 (en) * | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
| US6348191B1 (en) | 1986-07-08 | 2002-02-19 | Genetics Institute, Inc. | Production and use of IL-6 |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| PT858343E (pt) * | 1995-11-02 | 2004-07-30 | Schering Corp | Terapia por infusao continua de uma dose baixa de citoquina |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| EP2298900A1 (en) * | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
| TW589189B (en) * | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| WO2000037096A2 (en) * | 1998-12-22 | 2000-06-29 | Schering Corporation | Treatment of hepatitis c virus infections with interleukin-10 |
| ES2200646B1 (es) * | 2001-09-21 | 2005-05-01 | Fundacion Para La Investigacion Medica Aplicada | Uso de la cardiotrofina en enfermedades hepaticas. |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| RU2222345C2 (ru) * | 2002-01-21 | 2004-01-27 | Волчек Игорь Анатольевич | Фармацевтическая композиция цитокинового и иммуномодулирующего действия |
| US20050027110A1 (en) * | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
-
2005
- 2005-06-16 ES ES200501468A patent/ES2302402B1/es not_active Expired - Fee Related
-
2006
- 2006-06-16 CN CN2006800299002A patent/CN101257918B/zh not_active Expired - Fee Related
- 2006-06-16 BR BRPI0611988-3A patent/BRPI0611988A2/pt not_active IP Right Cessation
- 2006-06-16 CA CA2612282A patent/CA2612282C/en not_active Expired - Fee Related
- 2006-06-16 AU AU2006258966A patent/AU2006258966B8/en not_active Ceased
- 2006-06-16 WO PCT/ES2006/000353 patent/WO2006134195A2/es not_active Ceased
- 2006-06-16 EP EP06794028A patent/EP1905447A4/en not_active Withdrawn
- 2006-06-16 JP JP2008516350A patent/JP5154412B2/ja not_active Expired - Fee Related
- 2006-06-16 RU RU2008100307/15A patent/RU2413529C2/ru not_active IP Right Cessation
- 2006-06-16 MX MX2007016060A patent/MX2007016060A/es active IP Right Grant
- 2006-06-16 US US11/922,221 patent/US7829077B2/en not_active Expired - Fee Related
-
2010
- 2010-09-22 US US12/887,843 patent/US20110027224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008546672A (ja) | 2008-12-25 |
| JP5154412B2 (ja) | 2013-02-27 |
| AU2006258966A1 (en) | 2006-12-21 |
| CN101257918A (zh) | 2008-09-03 |
| ES2302402A1 (es) | 2008-07-01 |
| AU2006258966B2 (en) | 2011-11-17 |
| CA2612282A1 (en) | 2006-12-21 |
| EP1905447A2 (en) | 2008-04-02 |
| ES2302402B1 (es) | 2009-05-08 |
| RU2008100307A (ru) | 2009-07-27 |
| CA2612282C (en) | 2014-03-25 |
| US7829077B2 (en) | 2010-11-09 |
| WO2006134195A8 (es) | 2008-01-31 |
| RU2413529C2 (ru) | 2011-03-10 |
| WO2006134195A2 (es) | 2006-12-21 |
| CN101257918B (zh) | 2011-09-21 |
| AU2006258966B8 (en) | 2011-12-08 |
| WO2006134195A3 (es) | 2007-04-19 |
| BRPI0611988A2 (pt) | 2010-10-13 |
| US20090130055A1 (en) | 2009-05-21 |
| US20110027224A1 (en) | 2011-02-03 |
| EP1905447A4 (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110027224A1 (en) | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha | |
| KR101755058B1 (ko) | 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물 | |
| Gao et al. | STAT proteins–key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver | |
| JP4001379B2 (ja) | ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用 | |
| Lin et al. | Interferons: Success in anti-viral immunotherapy | |
| Marcello et al. | Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics | |
| Frese et al. | Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs | |
| De Maeyer et al. | Type I interferons | |
| Sato et al. | Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β | |
| Zhu et al. | Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication | |
| Castelruiz et al. | Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls | |
| George et al. | Interferon-α subtypes as an adjunct therapeutic approach for human immunodeficiency virus functional cure | |
| Ito et al. | Effects of tumor necrosis factor alpha on replication of varicella-zoster virus | |
| US20040034206A1 (en) | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | |
| Martínez-Espinoza et al. | Current landscape of IFN-λ: induction, inhibition, and potential clinical applications to treat respiratory viral infections | |
| Gruber et al. | Differential signaling of cmvIL‐10 through common variants of the IL‐10 receptor 1 | |
| US20090074721A1 (en) | Methods for treating viral infection with oral or injectibel drug solution | |
| WO2005016226A2 (en) | Pharmaceutical compositions comprising ccr5 antagonists | |
| JPWO2008004653A1 (ja) | ウイルス性疾患の予防又は治療剤 | |
| Lin et al. | [12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTS | |
| Huang et al. | [13] IN VITRO EVALUATION OF COMBINATION TREATMENT OF ACH-806 WITH INTERFERON; VX-950 AND NM 107 | |
| Masihi | Novel concepts for anti-infective activity of cytokines, chemokines and diverse agents | |
| Masihi | Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases | |
| Civeira et al. | Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls | |
| PRIETO | YURDANA CASTELRUIZ, ESTHER LARREA, PATRICIA BOYA, MAR?? A-PILAR CIVEIRA, AND JESU |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |